John Schmid's most recent trade in AnaptysBio Inc was a trade of 6,030 Common Stock done . Disclosure was reported to the exchange on June 15, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AnaptysBio Inc | John P. Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 6,030 | 37,652 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John P. Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 6,030 | 0 | - | - | Restricted Stock Unit | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 6,030 | 37,652 | - | 0 | Common Stock | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2026 | 6,030 | 0 | - | - | Restricted Stock Unit | |
| Design Therapeutics Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2026 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2026 | 190,549 | 605,389 (1%) | 0% | 0 | Common Stock | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 42,000 | 42,000 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 15,000 | 15,000 | - | - | Restricted Stock Unit | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 7,000 | 7,000 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2026 | 2,500 | 2,500 | - | - | Restricted Stock Unit | |
| UMB Fin Corp | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 129.24 per share. | 01 May 2026 | 116 | 33,370 (0%) | 0% | 129.2 | 14,992 | Common Stock |
| AnaptysBio Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Apr 2026 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Apr 2026 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Apr 2026 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 15,000 | 15,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Apr 2026 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Apr 2026 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 11,000 | 11,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Apr 2026 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 10,600 | 10,600 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Apr 2026 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 9,200 | 9,200 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | John P. Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Apr 2026 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Apr 2026 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 6,000 | 6,000 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 5,500 | 5,500 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John P. Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 20 Apr 2026 | 5,500 | 5,500 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 5,500 | 5,500 | - | - | Stock Option (right to buy) | |
| First Tracks Biotherapeutics | John P. Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2026 | 4,000 | 4,000 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | John P. Schmid | Director | Sale of securities on an exchange or to another person at price $ 55.71 per share. | 30 Mar 2026 | 12,596 | 39,671 (0%) | 0% | 55.7 | 701,707 | Common Stock |
| AnaptysBio Inc | John P. Schmid | Director | Sale of securities on an exchange or to another person at price $ 56.70 per share. | 30 Mar 2026 | 7,527 | 32,144 (0%) | 0% | 56.7 | 426,782 | Common Stock |
| AnaptysBio Inc | John P. Schmid | Director | Sale of securities on an exchange or to another person at price $ 57.40 per share. | 30 Mar 2026 | 522 | 31,622 (0%) | 0% | 57.4 | 29,962 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.95 per share. | 21 Mar 2026 | 14,196 | 414,840 (1%) | 0% | 10.9 | 155,446 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.25 per share. | 16 Mar 2026 | 22,405 | 429,036 (1%) | 0% | 9.2 | 207,246 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2026 | 26,253 | 465,040 (1%) | 0% | 0 | Common Stock | |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.52 per share. | 12 Mar 2026 | 13,599 | 451,441 (1%) | 0% | 9.5 | 129,462 | Common Stock |
| UMB Fin Corp | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 127.14 per share. | 30 Jan 2026 | 786 | 33,254 (0%) | 0% | 127.1 | 99,932 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 13.94 per share. | 13 Jan 2026 | 14,693 | 438,787 (1%) | 0% | 13.9 | 204,820 | Common Stock |
| AnaptysBio Inc | John Schmid P. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 5,500 | 5,500 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John Schmid P. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2026 | 4,000 | 4,000 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | John Schmid | Director | Other type of transaction at price $ 51.00 per share. | 23 Dec 2025 | 11,068 | 0 (0%) | 0% | 51 | 564,468 | Common Stock |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2025 | 6,030 | 52,267 (0%) | 0% | 0 | Common Stock | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2025 | 6,030 | 0 | - | - | Restricted Stock Unit | |
| Design Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jun 2025 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Purchase of securities on an exchange or from another person at price $ 13.39 per share. | 06 Jun 2025 | 7,600 | 453,480 (1%) | 0% | 13.4 | 101,778 | Common Stock |
| AnaptysBio Inc | John Schmid | Director | Other type of transaction at price $ 18.18 per share. | 25 Mar 2025 | 11,068 | 11,068 (0%) | 0% | 18.2 | 201,241 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Mar 2025 | 145,519 | 445,880 (1%) | 0% | 0 | Common Stock | |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 15.41 per share. | 16 Mar 2025 | 22,405 | 312,016 (0%) | 0% | 15.4 | 345,261 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.10 per share. | 16 Mar 2025 | 11,655 | 300,361 (0%) | 0% | 16.1 | 187,646 | Common Stock |
| UMB Fin Corp | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 32,468 | 32,468 (0%) | 0% | - | Common Stock | |
| UMB Fin Corp | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 21,818 | 21,818 (0%) | 0% | - | Common Stock | |
| UMB Fin Corp | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 2,629 | 2,629 (0%) | 0% | - | Common Stock | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.55 per share. | 13 Jan 2025 | 21,692 | 25,592 (0%) | 0% | 4.6 | 98,699 | Common Stock |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 21,692 | 0 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 20,645 | 0 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.54 per share. | 13 Jan 2025 | 20,645 | 46,237 (0%) | 0% | 8.5 | 176,308 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.37 per share. | 13 Jan 2025 | 14,350 | 334,421 (0%) | 0% | 20.4 | 292,310 | Common Stock |
| Poseida Therapeutics Inc | John Schmid | Director | 08 Jan 2025 | 58,950 | 0 | - | - | Common Stock | ||
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 32,076 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 28,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 27,350 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 25,833 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 08 Jan 2025 | 16,038 | 0 | - | - | Stock Option (Right to Buy) | |
| AnaptysBio Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 16,510 | 16,510 | - | - | Stock Option (right to buy) | |
| AnaptysBio Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2025 | 6,030 | 6,030 | - | - | Restricted Stock Unit | |
| Heartland Financial USA Inc | John K. Schmidt | Director | Sale of securities on an exchange or to another person at price $ 68.32 per share. | 11 Nov 2024 | 22,500 | 60,541 (0%) | 0% | 68.3 | 1,537,200 | Common Stock |
| Heartland Financial USA Inc | John K. Schmidt | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Nov 2024 | 3,500 | 57,041 (0%) | 0% | 0 | Common Stock | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | 12 Aug 2024 | 4,515 | 25,200 (0%) | 0% | 2.2 | 10,147 | Common Stock | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | 09 Aug 2024 | 4,285 | 20,685 (0%) | 0% | 2.4 | 10,134 | Common Stock | |
| Heartland Financial USA Inc | John K. Schmidt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 2,534 | 83,041 (0%) | 0% | 0 | Common Stock | |
| Heartland Financial USA Inc | John K. Schmidt | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Jun 2024 | 2,534 | 0 | - | - | 2023 Restricted Stock Units | |
| Poseida Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 27,350 | 27,350 | - | - | Stock Option (Right to buy) | |
| Poseida Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2024 | 19,650 | 58,950 | - | 0 | Common Stock | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 0 | - | - | Restricted Stock Unit | |
| AnaptysBio Inc | John Schmid | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2024 | 3,900 | 3,900 (0%) | 0% | 0 | Common Stock | |
| Design Therapeutics Inc | John Schmid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 19,000 | 19,000 | - | - | Stock Option (right to buy) | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | 05 Jun 2024 | 50,000 | 113,159 (0%) | 0% | 0 | Common Stock | ||
| Heartland Financial USA Inc | John K. Schmidt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 1,992 | 1,992 | - | - | 2024 Time-Based Restricted Stock | |
| Xeris Biopharma Holdings Inc | John Schmid | Director | 10 May 2024 | 5,400 | 16,400 (0%) | 0% | 1.9 | 10,314 | Common Stock | |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Sale of securities on an exchange or to another person at price $ 37.62 per share. | 06 May 2024 | 12,666 | 348,771 (0%) | 0% | 37.6 | 476,556 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Sale of securities on an exchange or to another person at price $ 37.63 per share. | 06 May 2024 | 12,666 | 361,437 (0%) | 0% | 37.6 | 476,613 | Common Stock |
| Design Therapeutics Inc | John Schmid | Director | Purchase of securities on an exchange or from another person at price $ 3.74 per share. | 22 Mar 2024 | 17,809 | 26,965 | - | 3.7 | 66,606 | Common Stock |
| Design Therapeutics Inc | John Schmid | Director | Purchase of securities on an exchange or from another person at price $ 3.62 per share. | 22 Mar 2024 | 9,156 | 9,156 | - | 3.6 | 33,133 | Common Stock |
| Caleres Inc | John W. Schmidt | Director, President & CEO, Caleres | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Mar 2024 | 54,812 | 374,103 (0%) | 0% | 0 | Common Stock |